TY - JOUR
KW - automation and high-throughput systems
KW - complex disease modeling
KW - iPSC-derived organoids
AU - Xingrui Mou
AU - Nathan Dale
AU - Kiran Ramnarine
AU - Filippo Cipriani
AB - Complex diseases arise from genetic, environmental, and lifestyle factors, the combination of which is difficult to model. Conventional animal and 2D cell culture models have limitations in scalability, reproducibility, or human relevance. Human-induced pluripotent stem cells (iPSCs) can be differentiated into 3D organoids that better mimic human biology. However, organoid protocols can be lengthy, variable, and labor-intensive, limiting high-throughput applications. Suspension bioreactors and multilineage differentiation have improved yield and function, but challenges remain in tissue maturity, vascularization, and consistency. Automated high-throughput liquid handling systems are emerging as a solution, enabling large-scale, reproducible production. Here, we discuss how combining iPSC-derived organoids with automation is poised to transform disease modeling and drug development.
BT - Trends in Biotechnology
DA - 2026-05-14
DO - 10.1016/j.tibtech.2026.04.013
N2 - Complex diseases arise from genetic, environmental, and lifestyle factors, the combination of which is difficult to model. Conventional animal and 2D cell culture models have limitations in scalability, reproducibility, or human relevance. Human-induced pluripotent stem cells (iPSCs) can be differentiated into 3D organoids that better mimic human biology. However, organoid protocols can be lengthy, variable, and labor-intensive, limiting high-throughput applications. Suspension bioreactors and multilineage differentiation have improved yield and function, but challenges remain in tissue maturity, vascularization, and consistency. Automated high-throughput liquid handling systems are emerging as a solution, enabling large-scale, reproducible production. Here, we discuss how combining iPSC-derived organoids with automation is poised to transform disease modeling and drug development.
PY - 2026
T2 - Trends in Biotechnology
TI - Automated stem cell-derived organoid platforms for disease modeling
UR - https://www.sciencedirect.com/science/article/pii/S0167779926001484
Y2 - 2026-05-18
SN - 0167-7799
ER -